OSPIN GMBH

Their core work

OSPIN is a Berlin-based biotech SME specializing in bioreactor technology and bioprocess automation for advanced 3D cell culture systems. They provide the hardware and software infrastructure that enables researchers to grow, monitor, and test complex tissue models — from osteochondral scaffolds to cardiac microtissues. Their contribution to EU projects centers on delivering bioreactor platforms for organ-on-chip and organotypic model development, supporting drug screening and toxicity testing applications.

What they specialise in

How they've shifted over time

OSPIN's early H2020 involvement (2019) focused on musculoskeletal applications — iPSC-seeded scaffolds for osteoporosis and osteoarthritis, paired with personalized medicine approaches and nanofiber-based drug delivery. By 2021, their focus shifted decisively toward cardiac tissue engineering, electrophysiology, biosensing, and organ-on-chip platforms, reflecting a move from passive scaffold support toward active, instrumented tissue models with real-time monitoring capabilities.

OSPIN is moving from basic bioreactor provision toward integrated organ-on-chip platforms with built-in sensing and stimulation — positioning themselves at the intersection of bioprocessing and digital health.

How they like to work

OSPIN operates exclusively as a participant, never as coordinator, which is typical for a technology SME contributing specialized equipment and process know-how to research-led consortia. With 21 unique partners across 14 countries from just 3 projects, they join broad international networks rather than small focused teams. This suggests they are a sought-after technology provider that research groups bring in for their bioreactor capabilities.

Despite only 3 projects, OSPIN has built a remarkably wide network of 21 partners across 14 countries, indicating participation in large MSCA-RISE mobility consortia that span Europe and beyond.

What sets them apart

OSPIN occupies a specific niche as a commercial bioreactor and bioprocess automation provider embedded in academic tissue engineering consortia. Unlike university labs that build one-off systems, OSPIN offers productized bioreactor platforms that can be deployed across multiple research groups. For consortium builders, they bring the engineering and manufacturing capability to turn lab-scale tissue models into reproducible, automated systems.

Highlights from their portfolio

• EMAPS-Cardio
  Their largest project (EUR 418,500, 76% of total funding) and a strategic pivot into cardiac organ-on-chip with electromechanical stimulation and biosensing integration.
• ActiTOX
  Addresses the growing regulatory need for alternatives to animal testing by developing organotypic 3D models for nanoparticle toxicity screening.